Use of Hydroxychloroquine Is Associated with Improved Lipid Profile in Rheumatoid Arthritis Patients

Jose Felix Restrepo, Inmaculada Del Rincon, Emily Molina, Daniel F. Battafarano, Agustin Escalante

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Background/Purpose We examined the association between hydroxychloroquine (HCQ) and plasma lipid and glucose levels in rheumatoid arthritis (RA) cohort. Methods This is a retrospective cohort analysis of 1261 RA patients comparing fasting lipid profiles and plasma glucose between patients who were and were not taking HCQ. We divided patients into 3 groups based on HCQ exposure during follow-up: Those who had never taken HCQ, those who took it intermittently, and those who took it continuously. We used multivariable models and propensity scoring to compensate for the effect of nonrandom treatment assignment. Results We followed 1261 RA patients for a total of 4605 observations between 1996 and 2014. After adjusting for age, sex, ethnicity, other disease-modifying antirheumatic drugs (DMARDs), lipid-lowering medications, body mass index (BMI), and smoking, patients taking HCQ at baseline had significantly lower total cholesterol (TC) (P ≤ 0.001), low-density lipoprotein (LDL) (P ≤ 0.001), triglycerides (P = 0.013), and lipid profile ratios TC/high-density lipoprotein (HDL) (P ≤ 0.001) and LDL/HDL (P ≤ 0.001), as well as higher HDL (P ≤ 0.001). In longitudinal analyses, after adjusting for confounders, patients who continuously took HCQ showed significantly lower TC, LDL, TC/HDL, and LDL/HDL and higher HDL (P ≤ 0.01). Fasting plasma glucose levels were not significantly associated with HCQ exposure. Conclusions Hydroxychloroquine use was associated with lower lipid levels but not with the plasma glucose in this RA cohort. These findings support the need for a randomized trial to establish the role of HCQ in cardiovascular disease prevention in RA patients.

Original languageEnglish (US)
Pages (from-to)144-148
Number of pages5
JournalJournal of Clinical Rheumatology
Volume23
Issue number3
DOIs
StatePublished - Apr 1 2017

Fingerprint

Hydroxychloroquine
Rheumatoid Arthritis
Lipids
HDL Lipoproteins
LDL Lipoproteins
Glucose
HDL Cholesterol
Fasting
Cholesterol
Antirheumatic Agents
Triglycerides
Body Mass Index
Cohort Studies
Cardiovascular Diseases
Smoking

Keywords

  • Glucose
  • Hydroxychloroquine
  • Lipids
  • Rheumatoid arthritis

ASJC Scopus subject areas

  • Rheumatology

Cite this

Use of Hydroxychloroquine Is Associated with Improved Lipid Profile in Rheumatoid Arthritis Patients. / Restrepo, Jose Felix; Del Rincon, Inmaculada; Molina, Emily; Battafarano, Daniel F.; Escalante, Agustin.

In: Journal of Clinical Rheumatology, Vol. 23, No. 3, 01.04.2017, p. 144-148.

Research output: Contribution to journalArticle

@article{99bcc7f43a4f4e44bbba011139fb1b1a,
title = "Use of Hydroxychloroquine Is Associated with Improved Lipid Profile in Rheumatoid Arthritis Patients",
abstract = "Background/Purpose We examined the association between hydroxychloroquine (HCQ) and plasma lipid and glucose levels in rheumatoid arthritis (RA) cohort. Methods This is a retrospective cohort analysis of 1261 RA patients comparing fasting lipid profiles and plasma glucose between patients who were and were not taking HCQ. We divided patients into 3 groups based on HCQ exposure during follow-up: Those who had never taken HCQ, those who took it intermittently, and those who took it continuously. We used multivariable models and propensity scoring to compensate for the effect of nonrandom treatment assignment. Results We followed 1261 RA patients for a total of 4605 observations between 1996 and 2014. After adjusting for age, sex, ethnicity, other disease-modifying antirheumatic drugs (DMARDs), lipid-lowering medications, body mass index (BMI), and smoking, patients taking HCQ at baseline had significantly lower total cholesterol (TC) (P ≤ 0.001), low-density lipoprotein (LDL) (P ≤ 0.001), triglycerides (P = 0.013), and lipid profile ratios TC/high-density lipoprotein (HDL) (P ≤ 0.001) and LDL/HDL (P ≤ 0.001), as well as higher HDL (P ≤ 0.001). In longitudinal analyses, after adjusting for confounders, patients who continuously took HCQ showed significantly lower TC, LDL, TC/HDL, and LDL/HDL and higher HDL (P ≤ 0.01). Fasting plasma glucose levels were not significantly associated with HCQ exposure. Conclusions Hydroxychloroquine use was associated with lower lipid levels but not with the plasma glucose in this RA cohort. These findings support the need for a randomized trial to establish the role of HCQ in cardiovascular disease prevention in RA patients.",
keywords = "Glucose, Hydroxychloroquine, Lipids, Rheumatoid arthritis",
author = "Restrepo, {Jose Felix} and {Del Rincon}, Inmaculada and Emily Molina and Battafarano, {Daniel F.} and Agustin Escalante",
year = "2017",
month = "4",
day = "1",
doi = "10.1097/RHU.0000000000000502",
language = "English (US)",
volume = "23",
pages = "144--148",
journal = "Journal of Clinical Rheumatology",
issn = "1076-1608",
publisher = "Lippincott Williams and Wilkins",
number = "3",

}

TY - JOUR

T1 - Use of Hydroxychloroquine Is Associated with Improved Lipid Profile in Rheumatoid Arthritis Patients

AU - Restrepo, Jose Felix

AU - Del Rincon, Inmaculada

AU - Molina, Emily

AU - Battafarano, Daniel F.

AU - Escalante, Agustin

PY - 2017/4/1

Y1 - 2017/4/1

N2 - Background/Purpose We examined the association between hydroxychloroquine (HCQ) and plasma lipid and glucose levels in rheumatoid arthritis (RA) cohort. Methods This is a retrospective cohort analysis of 1261 RA patients comparing fasting lipid profiles and plasma glucose between patients who were and were not taking HCQ. We divided patients into 3 groups based on HCQ exposure during follow-up: Those who had never taken HCQ, those who took it intermittently, and those who took it continuously. We used multivariable models and propensity scoring to compensate for the effect of nonrandom treatment assignment. Results We followed 1261 RA patients for a total of 4605 observations between 1996 and 2014. After adjusting for age, sex, ethnicity, other disease-modifying antirheumatic drugs (DMARDs), lipid-lowering medications, body mass index (BMI), and smoking, patients taking HCQ at baseline had significantly lower total cholesterol (TC) (P ≤ 0.001), low-density lipoprotein (LDL) (P ≤ 0.001), triglycerides (P = 0.013), and lipid profile ratios TC/high-density lipoprotein (HDL) (P ≤ 0.001) and LDL/HDL (P ≤ 0.001), as well as higher HDL (P ≤ 0.001). In longitudinal analyses, after adjusting for confounders, patients who continuously took HCQ showed significantly lower TC, LDL, TC/HDL, and LDL/HDL and higher HDL (P ≤ 0.01). Fasting plasma glucose levels were not significantly associated with HCQ exposure. Conclusions Hydroxychloroquine use was associated with lower lipid levels but not with the plasma glucose in this RA cohort. These findings support the need for a randomized trial to establish the role of HCQ in cardiovascular disease prevention in RA patients.

AB - Background/Purpose We examined the association between hydroxychloroquine (HCQ) and plasma lipid and glucose levels in rheumatoid arthritis (RA) cohort. Methods This is a retrospective cohort analysis of 1261 RA patients comparing fasting lipid profiles and plasma glucose between patients who were and were not taking HCQ. We divided patients into 3 groups based on HCQ exposure during follow-up: Those who had never taken HCQ, those who took it intermittently, and those who took it continuously. We used multivariable models and propensity scoring to compensate for the effect of nonrandom treatment assignment. Results We followed 1261 RA patients for a total of 4605 observations between 1996 and 2014. After adjusting for age, sex, ethnicity, other disease-modifying antirheumatic drugs (DMARDs), lipid-lowering medications, body mass index (BMI), and smoking, patients taking HCQ at baseline had significantly lower total cholesterol (TC) (P ≤ 0.001), low-density lipoprotein (LDL) (P ≤ 0.001), triglycerides (P = 0.013), and lipid profile ratios TC/high-density lipoprotein (HDL) (P ≤ 0.001) and LDL/HDL (P ≤ 0.001), as well as higher HDL (P ≤ 0.001). In longitudinal analyses, after adjusting for confounders, patients who continuously took HCQ showed significantly lower TC, LDL, TC/HDL, and LDL/HDL and higher HDL (P ≤ 0.01). Fasting plasma glucose levels were not significantly associated with HCQ exposure. Conclusions Hydroxychloroquine use was associated with lower lipid levels but not with the plasma glucose in this RA cohort. These findings support the need for a randomized trial to establish the role of HCQ in cardiovascular disease prevention in RA patients.

KW - Glucose

KW - Hydroxychloroquine

KW - Lipids

KW - Rheumatoid arthritis

UR - http://www.scopus.com/inward/record.url?scp=85014724711&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85014724711&partnerID=8YFLogxK

U2 - 10.1097/RHU.0000000000000502

DO - 10.1097/RHU.0000000000000502

M3 - Article

VL - 23

SP - 144

EP - 148

JO - Journal of Clinical Rheumatology

JF - Journal of Clinical Rheumatology

SN - 1076-1608

IS - 3

ER -